- Home
- INFU vs FENC Comparison
INFU vs FENC Comparison
Compare INFU & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INFU
- FENC
- Stock Information
- Founded
- INFU 2005
- FENC 1996
- Country
- INFU United States
- FENC United States
- Employees
- INFU N/A
- FENC N/A
- Industry
- INFU Medical/Dental Instruments
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INFU Health Care
- FENC Health Care
- Exchange
- INFU Nasdaq
- FENC Nasdaq
- Market Cap
- INFU 180.4M
- FENC 225.4M
- IPO Year
- INFU N/A
- FENC 2001
- Fundamental
- Price
- INFU $9.75
- FENC $8.67
- Analyst Decision
- INFU Strong Buy
- FENC Strong Buy
- Analyst Count
- INFU 1
- FENC 2
- Target Price
- INFU $12.00
- FENC $13.50
- AVG Volume (30 Days)
- INFU 301.2K
- FENC 56.7K
- Earning Date
- INFU 11-06-2025
- FENC 11-06-2025
- Dividend Yield
- INFU N/A
- FENC N/A
- EPS Growth
- INFU 2168.02
- FENC N/A
- EPS
- INFU 0.24
- FENC N/A
- Revenue
- INFU $139,886,000.00
- FENC $33,302,000.00
- Revenue This Year
- INFU $9.07
- FENC $0.18
- Revenue Next Year
- INFU $6.55
- FENC $52.59
- P/E Ratio
- INFU $41.71
- FENC N/A
- Revenue Growth
- INFU 8.13
- FENC N/A
- 52 Week Low
- INFU $4.61
- FENC $3.96
- 52 Week High
- INFU $11.04
- FENC $9.42
- Technical
- Relative Strength Index (RSI)
- INFU 53.52
- FENC 48.25
- Support Level
- INFU $9.82
- FENC $8.42
- Resistance Level
- INFU $10.33
- FENC $9.11
- Average True Range (ATR)
- INFU 0.39
- FENC 0.32
- MACD
- INFU -0.20
- FENC -0.04
- Stochastic Oscillator
- INFU 1.53
- FENC 29.14
About INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.